62

Neith Corporation

6236 · TWO · Healthcare / Biotechnology

13.55TWD-0.25 (-1.81%)

Price History

Full chart

Market Stats

Previous Close13.80
Open13.80
Day Range13.50 – 13.80
52-Week Range13.85 – 29.45
Volume4.00K
Market Cap703.95M
P/E (TTM)1690.00
Forward P/E0.00
EPS0.01
Dividend Yield0.00%
Beta-0.14
50-Day Avg17.31
200-Day Avg20.04

About

Neith Corporation engages in the biotechnology, medical cosmetics, and preventive medicine businesses. The company provides nutritional products, including L-One, a liquid formula for maintaining eye health; EPlus, a multiple enzyme supplement; and other nutritional products under the King One name. It also offers genetic testing services. In addition, the company offers energy and dual-purpose mattresses, energy masks, energy silicon gel necklaces, energy waistbands, energy heating stones, massage rods, and water purifiers, as well as Ganbanyoku, an energy stone spa bed. Further, it offers beauty care products, such as cell regeneration and rejuvenation series skin care products; home energy products; and microcontrollers and peripherals. Neith Corporation was formerly known as Come True Biomedical Inc. Neith Corporation was incorporated in 1997 and is based in Taichung, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOYuefeng Lin
  • Employees0
  • HeadquartersNo. 51, GongYi Road, Taichung, Taiwan, 408, Taiwan
  • Websitehttps://www.neithcorp.com

Leadership

  • Yuefeng LinManager
  • Yi Fang WuAccounting Supervisor

Financials

Income Statement

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue31.39M32.06M39.90M45.57M36.15M
Growth (%)-+2.13%+24.48%+14.20%-20.68%
Cost of Revenue16.88M18.68M21.88M11.85M5.98M
Gross Profit14.51M13.37M18.02M33.72M30.16M
Gross Margin46.22%41.72%45.16%73.99%83.45%
Operating Expense23.70M42.43M66.87M58.60M31.09M
Operating Income-9.20M-29.05M-48.85M-24.89M-923.00K
Operating Margin-29.29%-90.63%-122.43%-54.61%-2.55%
EBITDA--18.49M-33.61M-12.08M7.84M
EBITDA Margin--57.69%-84.23%-26.51%21.70%
Net Income-5.35M-23.69M-40.03M-16.88M3.16M
Net Income Margin-17.05%-73.89%-100.33%-37.05%8.74%
R&D2.47M11.69M30.95M26.46M9.48M
R&D as % of Total Revenue7.88%36.48%77.56%58.07%26.24%
Interest Expense50.00K71.00K165.00K53.00K180.00K
Interest Expense % of Total Revenue0.16%0.22%0.41%0.12%0.50%

Balance Sheet

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets76.75M228.86M192.15M170.88M167.94M
Total Liabilities5.08M20.37M17.43M16.57M13.10M
Total Equity71.67M208.49M174.72M154.32M154.84M
Cash36.07M181.78M153.85M133.09M141.21M

Cash Flow

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow7.46M-26.46M-17.64M-27.99M9.29M
Capital Expenditure1.50M7.71M000
Free Cash Flow5.96M-34.16M-17.64M-27.99M9.29M
FCF to OCF79.88%129.13%100.00%100.00%100.00%

Key Statistics & Ratios

Market Cap703.95M
Enterprise Value587.15M
Trailing P/E1690.00
Forward P/E0.00
Price / Sales22.11
Price / Book4.63
EPS0.01
Book Value3.74
Revenue (TTM)31.84M
Gross Profit (TTM)26.70M
EBITDA-844.00K
Profit Margin1.02%
Operating Margin-9.72%
Return on Equity0.21%
Return on Assets-0.81%
Shares Outstanding41.65M
Shares Float5.05M
Beta-0.14
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Feb 12, 20080.21:1